Thyroid Clinical Trials

9 recruiting

Thyroid Trials at a Glance

367 actively recruiting trials for thyroid are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Not Applicable with 96 trials, with the heaviest enrollment activity in Houston, Shanghai, and New York. Lead sponsors running thyroid studies include M.D. Anderson Cancer Center, Fudan University, and IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Treatments under study

About Thyroid Clinical Trials

Looking for clinical trials for Thyroid? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thyroid trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thyroid clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 367 trials

Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting

Studies on Tumors of the Thyroid

Thyroid CancerPapillary Thyroid CancerFollicular Thyroid Cancer+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,500 enrolled1 locationNCT00001160
Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Endocrine TumorsNeuroblastomaThyroid Neoplasms+2 more
National Cancer Institute (NCI)2,415 enrolled1 locationNCT01005654
Recruiting

Natural History of Thyroid Function Disorders

HypothyroidismHyperthyroidismGrave's Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,500 enrolled1 locationNCT00001159
Recruiting

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

Non-Medullary Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)500 enrolled1 locationNCT01109420
Recruiting
Phase 3

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
Ascendis Pharma Bone Diseases A/S36 enrolled2 locationsNCT07081997
Recruiting

Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism

Efficacy and SafetyHyperthyroidism/ThyrotoxicosisComplication Rate+1 more
Chinese PLA General Hospital454 enrolled1 locationNCT07557810
Recruiting
Not Applicable

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

Thyroid Carcinoma
M.D. Anderson Cancer Center15 enrolled2 locationsNCT07218315
Recruiting

Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules

Benign Thyroid Nodule
University Hospital, Ghent50 enrolled3 locationsNCT07237373
Recruiting

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Thyroid CancerThyroidRefractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center100 enrolled1 locationNCT05733013
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 2

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled1 locationNCT06959511
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaThyroid CancerGlioma
Pfizer124 enrolled77 locationsNCT05538130
Recruiting
Phase 2Phase 3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting
Phase 2

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Metastic Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)54 enrolled1 locationNCT04927416
Recruiting
Phase 2

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled1 locationNCT03841617
Recruiting

Oropharynx (OPX) Biomarker Trial

Head and Neck CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+8 more
Mayo Clinic560 enrolled1 locationNCT06356272
Recruiting
Phase 2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Thyroid Cancer
Thomas Hope62 enrolled1 locationNCT06961084
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Not Applicable

qCON/qNOX-Guided Anesthesia in Patients Undergoing Thyroidectomy Surgery

Anesthesia Depth MonitoringThyroid SurgeriesIntraoperative Analgesic Use
Kayseri City Hospital90 enrolled1 locationNCT07445659